Control Bionics Ltd Asset Resilience Ratio
Control Bionics Ltd asset resilience ratio. Control Bionics Ltd (CBL) has an Asset Resilience Ratio of 0.95% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Control Bionics Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Control Bionics Ltd (2016–2024)
Asset resilience ratio of Control Bionics Ltd from 2016 to 2024. This chart shows how Control Bionics Ltd's Asset Resilience Ratio has changed over time. Read Control Bionics Ltd (CBL) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Control Bionics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Control Bionics Ltd (CBL) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$77.92K | 0.95% |
| Total Liquid Assets | AU$77.92K | 0.95% |
Asset Resilience Insights
- Limited Liquidity: Control Bionics Ltd maintains only 0.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Control Bionics Ltd Industry Peers by Asset Resilience Ratio
Compare Control Bionics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Ningbo David Medical Device Co Ltd
SHE:300314 |
Medical Devices | 5.11% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
MODULIGHT OY EO 1
F:78W |
Medical Devices | 15.99% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Nova EYE Medical Ltd
AU:EYE |
Medical Devices | 11.08% |
|
Promimic AB
ST:PRO |
Medical Devices | 8.62% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
Control Bionics Ltd Asset Resilience Ratio by Year (2016–2024)
Control Bionics Ltd asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Control Bionics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.95% | AU$77.92K ≈ $55.14K |
AU$8.23 Million ≈ $5.83 Million |
+0.08pp |
| 2023-12-31 | 0.86% | AU$77.92K ≈ $55.14K |
AU$9.03 Million ≈ $6.39 Million |
+0.22pp |
| 2022-12-31 | 0.65% | AU$56.19K ≈ $39.76K |
AU$8.70 Million ≈ $6.15 Million |
+0.23pp |
| 2021-12-31 | 0.42% | AU$56.19K ≈ $39.76K |
AU$13.44 Million ≈ $9.51 Million |
+0.35pp |
| 2020-12-31 | 0.07% | AU$13.09K ≈ $9.26K |
AU$18.35 Million ≈ $12.99 Million |
-0.56pp |
| 2016-12-31 | 0.63% | AU$7.32 Million ≈ $5.18 Million |
AU$1.16 Billion ≈ $819.21 Million |
-- |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more